Outlook For Biotech Sector

Brad Loncar says that some of the headwinds facing the biotech sector are FTC scrutiny of mergers, drug pricing legislation, strict FDA reviews, and rising interest rates. He recommends that investors look to diversify biotech investing outside of the U.S.